A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia

Trial Profile

A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Aripiprazole (Primary) ; Aripiprazole
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE-EU
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 21 Oct 2014 Results of a post hoc analysis on the week 38 changes in the 5 Marder PANSS dimensions presented at 27th Annual Congress of European College of Neuropsychopharmacology.
    • 20 Oct 2014 Results of a post-hoc analysis of trials NCT00705783 and NCT00706654 were presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 12 Feb 2014 Results from this trial contributed to the approval of once-monthly intramuscular aripiprazole in Canada based on information reported in an Otsuka Pharmaceutical and H. Lundbeck A/S media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top